/Investor DB

Amgen Ventures — 2019 Investments

2 investments dated 2019 · listed companies and verified rows first · show all

Nkarta, Inc.nkartatx.cominNASDAQ: NKTXAug 2019

Nkarta is a biotech company developing allogeneic CAR NK cell therapies for autoimmune diseases, aiming to offer safer and more accessible alternatives to autologous CAR-T treatments.

BiotechHealthtechSouth San Francisco, US

Paul Hastings(Executive Officer, Director)inPaul H.inMatthew Plunkett(Executive Officer)in

BoardMichael Dybbs(Director)Jill Carroll(Director)inTiba Aynechi(Director)in

Co-investorsNew Enterprise Associates (NEA)RA CapitalSamsara BioCapitalSR One Capital ManagementLogosNorwest Venture Partners+1 more

Other

Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.

Imago BioSciences, Inc.

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.